Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Action inhibitors |
Mechanism AKT gene inhibitors, Akt-1 inhibitors(Serine/threonine-protein kinase AKT1 inhibitors), Akt-2 inhibitors(Serine/threonine-protein kinase AKT2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H56ClN9O7 |
InChIKeyQMLFGZYEQAMKRK-SCQVZNLVSA-N |
CAS Registry2376136-61-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 02 Dec 2021 | |
Neoplasms | Preclinical | United States | 02 Dec 2021 |